Aliases:This biomarker is also known as:
- chemokine (C-C motif) ligand 27,
- small-inducible cytokine A27,
- small inducible cytokine subfamily A (Cys-Cys), member 27,
- CC chemokine ILC,
- cutaneous T-cell attracting chemokine,
- IL-11 R-alpha-locus chemokine,
- Small-inducible cytokine A27,
- cutaneous T-cell-attracting chemokine,
- IL-11 Ralpha-locus chemokine,
- C-C motif chemokine 27,
- Cutaneous T-cell-attracting chemokine,
CCL27 is a member of the CC cytokine family, and is involved in immunoregulatory and inflammatory processes. CC cytokines are characterized by two adjacent cysteines. CCL27 functions as a chemotactic factor that attracts skin-associated memory T-lymphocytes. CCL27 may also play a role in mediating homing of lymphocytes to cutaneous sites. CCL27 binds specifically to chemokine receptor 10 (CCR10).
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
CCL27 was present at higher levels among cases compared to controls with reasonable AUC values.
CCL27 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.